Dr. Joe Sammy Mendez, MD

Dr. Mendez practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Mendez's NPI, 1578819827, was assigned on July 24, 2012. Dr. Mendez graduated from University of California, San Francisco School of Medicine in 2012. Dr. Mendez holds Utah license 10766526-1205.

Dr. Mendez's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Mendez's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Mendez is also affiliated with University of Utah Hospital. The medical group on file is Intermountain Health. Dmand AI also links Dr. Mendez to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mendez practices, 4 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Mendez's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dmand AI has Dr. Mendez's licenses on file in 2 states: Utah and New York.

CMS data shows 362 Medicare services from Dr. Mendez across 3 procedure codes in 2024, for 68 Medicare patients. Medicare paid $17,944 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 68 Medicare patients who saw Dr. Mendez in 2024. The largest group is 65 to 74, with 37 patients. 62% of them have high blood pressure, and 51% have high cholesterol. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mendez's median patient age at 61, with 51% women.

In 2024, Dr. Mendez wrote 302 Medicare Part D claims for 59 patients. 70% of them were for generic drugs. CMS names the drug for 191 of them, across 10 drugs with 11 or more claims each, at $274,447 in total drug cost. In 2023, CMS named 98 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Mendez for performance year 2024, reported as part of a group. Dr. Mendez accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 17 papers to Dr. Mendez, published from 2016 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Brain Neoplasms, Central Nervous System Neoplasms and Astrocytoma. Dr. Mendez has published most often in J Neurooncol. Dr. Mendez's most frequent co-authors are Howard Colman, MD, Lindsay Morgan Burt, MD and Donald M. Cannon, MD.

Dmand AI links Dr. Mendez to 6 clinical trials, 2 of them phase 1/2 studies. 4 are still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Gliosarcoma. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 18 general payments to Dr. Mendez from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 35% of the total. Servier Pharmaceuticals LLC paid the most, $7,642. It also lists 14 research payments totaling $7,096 in 2023.

Dr. Mendez graduated from University of California, San Francisco School of Medicine in 2012.